Infectious Diseases Society of America (IDSA)’nın düzenlediği IDWeek 2015™’de sunulan veriler, 3 bileşenli DTaP aşısından beş doz alan okul çağındaki çocuklar arasında boğmacaya karşı korumanın yılda ortalama yüzde 27 düştüğünü ortaya koydu. Bu düşüş herhangi bir tip DTaP aşısından beş doz alan çocuklarda sağlanan korumanın düşüşüne benzer oranda. Araştırıcı Nicola P. Klein “Muhtemel boğmaca salgınlarından korunmanın en iyi yolu, mevcut aşıların daha uzun süre koruma sağlayacak şekilde yeniden formüle edilerek yeni boğmaca aşılarının geliştirilmesi” şeklinde konuşuyor.
SAN DIEGO — Waning of three-component DTaP 3 after five doses is similar to that of any other DTaP vaccines after five doses, according to data presented at IDWeek 2015.
“The findings suggest that among school-aged children who received five doses of a 3-component DTaP vaccine, protection against pertussis waned 27% per year on average, which was similar to waning protection among children who received five doses of any type of DTaP vaccines,” Nicola P. Klein, MD, PhD, co-director of the Kaiser Permanente Vaccine Study Center, in Oakland, California, told Infectious Diseases in Children. “Prevention of future pertussis outbreaks will be best achieved by developing new pertussis-containing vaccines or reformulating current vaccines to provide long-lasting immunity.”
Three hundred forty children aged 4 to 12 years were diagnosed with pertussis, and 3,843 children tested negative for pertussis after a fifth dose of DTaP 3. Almost 87% of study participants received DTaP 3. The study also included 462 children who tested positive for pertussis and 5,653 children who tested negative after a fifth dose of any type of DTaP vaccine.
Data indicated that the odds of a study participant becoming infected with pertussis increased 27% every year after the fifth dose of DTaP 3 (OR = 1.27; 95% CI, 1.1-1.46) compared with 30% after five doses of any DTaP (OR = 1.3 (95% CI, 1.15-1.46).
“[However], the DTaP vaccine is effective and remains an important tool for protection against whooping cough for children and the communities in which they live,” Klein said. “Following current CDC recommendations remains important.” – by David Costill
Klein NP, et al. Oral Abstract 1388. Presented at: IDWeek; Oct. 7-11, 2015; San Diego.
Disclosure: Klein reports being a grant investigator for and receiving research grants from GlaxoSmithKline; MedImmune; Merck; Novartis, Nuron Biotech; Pfizer; Protein Science, in which she also received research support; and Sanofi Pasteur.